HPV-associated oropharyngeal cancer

Sustained Locoregional Control With Deintensified Chemoradiotherapy for HPV Oropharyngeal Carcinoma

By MedXY 05/08/2026

A cohort study demonstrates that reduced-dose 60-Gy chemoradiotherapy effectively maintains locoregional control in HPV-positive oropharyngeal cancer patients while minimizing treatment toxicity, with 5-year survival rates exceeding 92%.

news Oncology Otorhinolaryngology

Determinants of Circulating Tumor HPV DNA in Surgically Treated Oropharyngeal Cancer

By MedXY 04/11/2026

This study identifies clinicopathologic factors linked to pre- and postoperative levels of circulating tumor HPV DNA (ctHPVDNA) in HPV-mediated oropharyngeal cancer patients treated with upfront surgery, offering insights for disease monitoring and clinical trial design.

Clinical Updates news Oncology Radiology Specialties

De-escalated Adjuvant Radiotherapy in HPV-Associated Oropharyngeal Cancer: Balancing Efficacy with Reduced Toxicity

By MedXY 09/21/2025

This phase 3 trial shows that de-escalated adjuvant radiotherapy reduces chronic grade 3+ toxicities compared to standard chemoradiotherapy in HPV-associated oropharyngeal cancer, potentially improving patient quality of life without compromising treatment.